{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T18:14:09Z","timestamp":1772043249445,"version":"3.50.1"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2017,7,3]],"date-time":"2017-07-03T00:00:00Z","timestamp":1499040000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s12325-017-0499-6","type":"journal-article","created":{"date-parts":[[2017,7,3]],"date-time":"2017-07-03T09:40:08Z","timestamp":1499074808000},"page":"1791-1814","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 Diabetes"],"prefix":"10.1007","volume":"34","author":[{"given":"Stefano","family":"Genovese","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edoardo","family":"Mannucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Ceriello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,7,3]]},"reference":[{"issue":"2","key":"499_CR1","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1210\/jcem-63-2-492","volume":"63","author":"MA Nauck","year":"1986","unstructured":"Nauck MA, Homberger E, Siegel EG, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab. 1986;63(2):492\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"499_CR2","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/j.1745-7599.2009.00455.x","volume":"21","author":"A Wick","year":"2009","unstructured":"Wick A, Newlin K. Incretin-based therapies: therapeutic rationale and pharmacological promise for type 2 diabetes. J Am Acad Nurse Pract. 2009;21(Suppl 1):623\u201330.","journal-title":"J Am Acad Nurse Pract"},{"issue":"2","key":"499_CR3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.regpep.2003.10.028","volume":"117","author":"LL Nielsen","year":"2004","unstructured":"Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept. 2004;117(2):77\u201388.","journal-title":"Regul Pept"},{"issue":"6","key":"499_CR4","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.2337\/dc06-2375","volume":"30","author":"D Kim","year":"2007","unstructured":"Kim D, MacConell L, Zhuang D, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care. 2007;30(6):1487\u201393.","journal-title":"Diabetes Care"},{"issue":"11","key":"499_CR5","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1089\/dia.2011.0050","volume":"13","author":"MB DeYoung","year":"2011","unstructured":"DeYoung MB, MacConell L, Sarin V, Trautmann M, Herbert P. Encapsulation of exenatide in poly-(d,l-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther. 2011;13(11):1145\u201354.","journal-title":"Diabetes Technol Ther"},{"issue":"1","key":"499_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2165\/11585880-000000000-00000","volume":"50","author":"M Fineman","year":"2011","unstructured":"Fineman M, Flanagan S, Taylor K, et al. Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing. Clin Pharmacokinet. 2011;50(1):65\u201374.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"499_CR7","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1177\/1932296815576186","volume":"9","author":"S LaRue","year":"2015","unstructured":"LaRue S, Malloy J. Evaluation of the dual-chamber pen design for the injection of exenatide once weekly for the treatment of type 2 diabetes. J Diabetes Sci Technol. 2015;9(4):815\u201321.","journal-title":"J Diabetes Sci Technol"},{"issue":"9645","key":"499_CR8","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(08)61206-4","volume":"372","author":"DJ Drucker","year":"2008","unstructured":"Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372(9645):1240\u201350.","journal-title":"Lancet"},{"issue":"8","key":"499_CR9","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1507\/endocrj.K09E-147","volume":"56","author":"K Iwamoto","year":"2009","unstructured":"Iwamoto K, Nasu R, Yamamura A, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes. Endocr J. 2009;56(8):951\u201362.","journal-title":"Endocr J"},{"issue":"6","key":"499_CR10","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/j.1463-1326.2012.01561.x","volume":"14","author":"MS Fineman","year":"2012","unstructured":"Fineman MS, Mace KF, Diamant M, et al. Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment. Diabetes Obes Metab. 2012;14(6):546\u201354.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"499_CR11","doi-asserted-by":"publisher","first-page":"252","DOI":"10.2337\/dc11-1107","volume":"35","author":"D Russell-Jones","year":"2012","unstructured":"Russell-Jones D, Cuddihy RM, Hanefeld M, et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care. 2012;35(2):252\u20138.","journal-title":"Diabetes Care"},{"issue":"9739","key":"499_CR12","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S0140-6736(10)60590-9","volume":"376","author":"RM Bergenstal","year":"2010","unstructured":"Bergenstal RM, Wysham C, Macconell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet. 2010;376(9739):431\u20139.","journal-title":"Lancet"},{"issue":"9733","key":"499_CR13","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1016\/S0140-6736(10)60406-0","volume":"375","author":"M Diamant","year":"2010","unstructured":"Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet. 2010;375(9733):2234\u201343.","journal-title":"Lancet"},{"issue":"5","key":"499_CR14","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1210\/jc.2010-2081","volume":"96","author":"T Blevins","year":"2011","unstructured":"Blevins T, Pullman J, Malloy J, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96(5):1301\u201310.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9861","key":"499_CR15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(12)61267-7","volume":"381","author":"JB Buse","year":"2013","unstructured":"Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013;381(9861):117\u201324.","journal-title":"Lancet"},{"key":"499_CR16","doi-asserted-by":"crossref","unstructured":"Fr\u00edas JP, Guja C, Hardy E, et al (2016) Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28\u00a0week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol;4(12):1004\u201316.","DOI":"10.1016\/S2213-8587(16)30267-4"},{"issue":"11","key":"499_CR17","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1089\/dia.2016.0107","volume":"18","author":"RR Henry","year":"2016","unstructured":"Henry RR, Klein EJ, Han J, Iqbal N. Efficacy and tolerability of exenatide once weekly over 6\u00a0years in patients with type 2 diabetes: an uncontrolled open-label extension of the DURATION-1 study. Diabetes Technol Ther. 2016;18(11):677\u201386.","journal-title":"Diabetes Technol Ther"},{"issue":"6","key":"499_CR18","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S2213-8587(14)70029-4","volume":"2","author":"M Diamant","year":"2014","unstructured":"Diamant M, Van Gaal L, Guerci B, et al. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial. Lancet Diabetes Endocrinol. 2014;2(6):464\u201373.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"499_CR19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.2040-1124.2012.00238.x","volume":"4","author":"L Ji","year":"2013","unstructured":"Ji L, Onishi Y, Ahn CW, et al. Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus. J Diabetes Investig. 2013;4(1):53\u201361.","journal-title":"J Diabetes Investig"},{"issue":"5","key":"499_CR20","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/jdi.12305","volume":"6","author":"YM Cho","year":"2015","unstructured":"Cho YM. Incretin physiology and pathophysiology from an Asian perspective. J Diabetes Investig. 2015;6(5):495\u2013507.","journal-title":"J Diabetes Investig"},{"issue":"6","key":"499_CR21","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1007\/s11892-015-0602-9","volume":"15","author":"D Yabe","year":"2015","unstructured":"Yabe D, Seino Y, Fukushima M, Seino S. \u03b2 cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in East Asians. Curr Diab Rep. 2015;15(6):602.","journal-title":"Curr Diab Rep"},{"issue":"6","key":"499_CR22","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.2337\/dc09-1914","volume":"33","author":"JB Buse","year":"2010","unstructured":"Buse JB, Drucker DJ, Taylor KL, et al. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care. 2010;33(6):1255\u201361.","journal-title":"Diabetes Care"},{"key":"499_CR23","first-page":"31","volume":"6","author":"L Macconell","year":"2013","unstructured":"Macconell L, Pencek R, Li Y, Maggs D, Porter L. Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years. Diabetes Metab Syndr Obes. 2013;6:31\u201341.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"4","key":"499_CR24","doi-asserted-by":"publisher","first-page":"683","DOI":"10.2337\/dc11-1233","volume":"35","author":"M Diamant","year":"2012","unstructured":"Diamant M, Van Gaal L, Stranks S, et al. Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84\u00a0weeks. Diabetes Care. 2012;35(4):683\u20139.","journal-title":"Diabetes Care"},{"issue":"10","key":"499_CR25","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1016\/j.clinthera.2012.09.007","volume":"34","author":"P Norwood","year":"2012","unstructured":"Norwood P, Liutkus JF, Haber H, Pintilei E, Boardman MK, Trautmann ME. Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2\u00a0years. Clin Ther. 2012;34(10):2082\u201390.","journal-title":"Clin Ther"},{"issue":"5","key":"499_CR26","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.2337\/dc12-1333","volume":"36","author":"M Davies","year":"2013","unstructured":"Davies M, Heller S, Sreenan S, et al. Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas. Diabetes Care. 2013;36(5):1368\u201376.","journal-title":"Diabetes Care"},{"key":"499_CR27","unstructured":"Vora JP, Malloy J, Zhou M, Hardy E, Iqbal N, Trautmann M. Daily blood glucose variability with exenatide once weekly vs. basal insulin in 3 RCTs. 74th Scientific Sessions of the American Diabetes Association, 2014. Poster 997."},{"issue":"3","key":"499_CR28","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/dom.12007","volume":"15","author":"DA Scott","year":"2013","unstructured":"Scott DA, Boye KS, Timlin L, Clark JF, Best JH. A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo. Diabetes Obes Metab. 2013;15(3):213\u201323.","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"499_CR29","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1185\/03007990802418851","volume":"24","author":"RA DeFronzo","year":"2008","unstructured":"DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin. 2008;24(10):2943\u201352.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"499_CR30","doi-asserted-by":"publisher","first-page":"T1","DOI":"10.1530\/JOE-13-0414","volume":"221","author":"L Bloemendaal van","year":"2014","unstructured":"van Bloemendaal L, Ten Kulve JS, la Fleur SE, Ijzerman RG, Diamant M. Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. J Endocrinol. 2014;221(1):T1\u201316.","journal-title":"J Endocrinol"},{"issue":"4","key":"499_CR31","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","volume":"87","author":"JJ Holst","year":"2007","unstructured":"Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409\u201339.","journal-title":"Physiol Rev"},{"issue":"12","key":"499_CR32","doi-asserted-by":"publisher","first-page":"4186","DOI":"10.2337\/db14-0849","volume":"63","author":"L Bloemendaal van","year":"2014","unstructured":"van Bloemendaal L, IJzerman RG, Ten Kulve JS, et al. GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans. Diabetes. 2014;63(12):4186\u201396.","journal-title":"Diabetes"},{"issue":"3","key":"499_CR33","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/sj.ijo.0802206","volume":"27","author":"AJ Kastin","year":"2003","unstructured":"Kastin AJ, Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord. 2003;27(3):313\u20138.","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"8","key":"499_CR34","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1210\/en.2011-0174","volume":"152","author":"SE Kanoski","year":"2011","unstructured":"Kanoski SE, Fortin SM, Arnold M, Grill HJ, Hayes MR. Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4. Endocrinology. 2011;152(8):3103\u201312.","journal-title":"Endocrinology"},{"key":"499_CR35","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12933-014-0171-2","volume":"14","author":"L Blonde","year":"2015","unstructured":"Blonde L, Pencek R, MacConell L. Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes. Cardiovasc Diabetol. 2015;14:12.","journal-title":"Cardiovasc Diabetol"},{"issue":"9","key":"499_CR36","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/j.mayocp.2015.06.005","volume":"90","author":"CH Wysham","year":"2015","unstructured":"Wysham CH. In reply\u2014long-term efficacy and safety of exenatide treatment. Mayo Clin Proc. 2015;90(9):1304\u20135.","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"499_CR37","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1210\/er.2011-1052","volume":"33","author":"JR Ussher","year":"2012","unstructured":"Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev. 2012;33(2):187\u2013215.","journal-title":"Endocr Rev"},{"key":"499_CR38","first-page":"621","volume":"8","author":"E Chiquette","year":"2012","unstructured":"Chiquette E, Toth PP, Ramirez G, Cobble M, Chilton R. Treatment with exenatide once weekly or twice daily for 30\u00a0weeks is associated with changes in several cardiovascular risk markers. Vasc Health Risk Manag. 2012;8:621\u20139.","journal-title":"Vasc Health Risk Manag"},{"key":"499_CR39","unstructured":"Guerci B, Schernthaner G, Gallwitz B, et al (2012) Long-term administration of exenatide and changes in body weight and markers of cardiovascular risk: a comparative study with glimepiride (Abstract 781). EASD annual meeting. (Berlin)"},{"key":"499_CR40","doi-asserted-by":"publisher","first-page":"d7771","DOI":"10.1136\/bmj.d7771","volume":"344","author":"T Vilsb\u00f8ll","year":"2012","unstructured":"Vilsb\u00f8ll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771.","journal-title":"BMJ"},{"issue":"6","key":"499_CR41","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1007\/s00125-013-2909-x","volume":"56","author":"P Valensi","year":"2013","unstructured":"Valensi P, Chiheb S, Fysekidis M. Insulin- and glucagon-like peptide-1-induced changes in heart rate and vagosympathetic activity: why they matter. Diabetologia. 2013;56(6):1196\u2013200.","journal-title":"Diabetologia"},{"issue":"10","key":"499_CR42","doi-asserted-by":"publisher","first-page":"594","DOI":"10.5414\/CP201462","volume":"49","author":"H Linnebjerg","year":"2011","unstructured":"Linnebjerg H, Seger M, Kothare PA, Hunt T, Wolka AM, Mitchell MI. A thorough QT study to evaluate the effects of singledose exenatide 10\u00a0\u03bcg on cardiac repolarization in healthy subjects. Int J Clin Pharmacol Ther. 2011;49(10):594\u2013604.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"4","key":"499_CR43","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/j.1365-2125.2012.04416.x","volume":"75","author":"B Darp\u00f6","year":"2013","unstructured":"Darp\u00f6 B, Sager P, MacConell L, et al. Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects. Br J Clin Pharmacol. 2013;75(4):979\u201389.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"499_CR44","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1093\/ajh\/hpt196","volume":"27","author":"M Katout","year":"2014","unstructured":"Katout M, Zhu H, Rutsky J, et al. Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression. Am J Hypertens. 2014;27(1):130\u20139.","journal-title":"Am J Hypertens"},{"key":"499_CR45","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.yjmcc.2014.08.022","volume":"76","author":"CW Younce","year":"2014","unstructured":"Younce CW, Niu J, Ayala J, et al. Exendin-4 improves cardiac function in mice overexpressing monocyte chemoattractant protein-1 in cardiomyocytes. J Mol Cell Cardiol. 2014;76:172\u20136.","journal-title":"J Mol Cell Cardiol"},{"issue":"8","key":"499_CR46","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1161\/01.CIR.0000139339.85840.DD","volume":"110","author":"LA Nikolaidis","year":"2004","unstructured":"Nikolaidis LA, Elahi D, Hentosz T, et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation. 2004;110(8):955\u201361.","journal-title":"Circulation"},{"issue":"3","key":"499_CR47","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1124\/jpet.106.100982","volume":"317","author":"T Zhao","year":"2006","unstructured":"Zhao T, Parikh P, Bhashyam S, et al. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther. 2006;317(3):1106\u201313.","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"499_CR48","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.jacc.2008.10.033","volume":"53","author":"L Timmers","year":"2009","unstructured":"Timmers L, Henriques JP, de Kleijn DP, et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol. 2009;53(6):501\u201310.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"499_CR49","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1161\/CIRCINTERVENTIONS.112.968388","volume":"5","author":"J L\u00f8nborg","year":"2012","unstructured":"L\u00f8nborg J, Kelb\u00e6k H, Vejlstrup N, et al. Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia. Circ Cardiovasc Interv. 2012;5(2):288\u201395.","journal-title":"Circ Cardiovasc Interv"},{"issue":"1","key":"499_CR50","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ijcard.2012.09.204","volume":"167","author":"FJ Bernink","year":"2013","unstructured":"Bernink FJ, Timmers L, Diamant M, et al. Effect of additional treatment with exenatide in patients with an acute myocardial infarction: the EXAMI study. Int J Cardiol. 2013;167(1):289\u201390.","journal-title":"Int J Cardiol"},{"key":"499_CR51","unstructured":"Exenatide study of cardiovascular event lowering trial (EXSCEL): A trial to evaluate cardiovascular outcomes after treatment with exenatide once weekly in patients with type 2 diabetes mellitus. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01144338 . Accessed 1 Jan 2015."},{"issue":"12","key":"499_CR52","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1111\/j.1463-1326.2012.01639.x","volume":"14","author":"T Ridge","year":"2012","unstructured":"Ridge T, Moretto T, MacConell L, et al. Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes. Diabetes Obes Metab. 2012;14(12):1097\u2013103.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"499_CR53","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/1753-0407.12208","volume":"7","author":"SK Paul","year":"2015","unstructured":"Paul SK, Maggs D, Klein K, Best JH. Dynamic risk factors associated with non-severe hypoglycemia in patients treated with insulin glargine or exenatide once weekly. J Diabetes. 2015;7(1):60\u20137.","journal-title":"J Diabetes"},{"issue":"7","key":"499_CR54","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.2337\/dc12-2713","volume":"36","author":"PC Butler","year":"2013","unstructured":"Butler PC, Elashoff M, Elashoff R, Gale EA. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care. 2013;36(7):2118\u201325.","journal-title":"Diabetes Care"},{"issue":"1","key":"499_CR55","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s00125-009-1515-4","volume":"53","author":"JS Nachnani","year":"2010","unstructured":"Nachnani JS, Bulchandani DG, Nookala A, et al. Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia. 2010;53(1):153\u20139.","journal-title":"Diabetologia"},{"issue":"5","key":"499_CR56","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.2337\/db11-1109","volume":"61","author":"B Gier","year":"2012","unstructured":"Gier B, Matveyenko AV, Kirakossian D, Dawson D, Dry SM, Butler PC. Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model. Diabetes. 2012;61(5):1250\u201362.","journal-title":"Diabetes"},{"issue":"5","key":"499_CR57","doi-asserted-by":"publisher","first-page":"834","DOI":"10.2337\/dc08-1755","volume":"32","author":"RA Noel","year":"2009","unstructured":"Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care. 2009;32(5):834\u20138.","journal-title":"Diabetes Care"},{"issue":"11","key":"499_CR58","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1111\/j.1464-5491.2012.03652.x","volume":"29","author":"M Wenten","year":"2012","unstructured":"Wenten M, Gaebler JA, Hussein M, et al. Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study. Diabet Med. 2012;29(11):1412\u20138.","journal-title":"Diabet Med"},{"issue":"11","key":"499_CR59","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.2337\/dc10-0482","volume":"33","author":"R Garg","year":"2010","unstructured":"Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care. 2010;33(11):2349\u201354.","journal-title":"Diabetes Care"},{"issue":"10","key":"499_CR60","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1089\/dia.2012.0075","volume":"14","author":"JA Romley","year":"2012","unstructured":"Romley JA, Goldman DP, Solomon M, McFadden D, Peters AL. Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured population. Diabetes Technol Ther. 2012;14(10):904\u201311.","journal-title":"Diabetes Technol Ther"},{"issue":"2","key":"499_CR61","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.diabres.2012.09.008","volume":"98","author":"C Alves","year":"2012","unstructured":"Alves C, Batel-Marques F, Macedo AF. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. Diabetes Res Clin Pract. 2012;98(2):271\u201384.","journal-title":"Diabetes Res Clin Pract"},{"key":"499_CR62","doi-asserted-by":"publisher","first-page":"g2366","DOI":"10.1136\/bmj.g2366","volume":"348","author":"L Li","year":"2014","unstructured":"Li L, Shen J, Bala MM, et al. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. BMJ. 2014;348:g2366.","journal-title":"BMJ"},{"issue":"1","key":"499_CR63","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1053\/j.gastro.2011.05.019","volume":"141","author":"J Spranger","year":"2011","unstructured":"Spranger J, Gundert-Remy U, Stammschulte T. GLP-1-based therapies: the dilemma of uncertainty. Gastroenterology. 2011;141(1):20\u20133.","journal-title":"Gastroenterology"},{"issue":"9","key":"499_CR64","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1056\/NEJMp1314078","volume":"370","author":"AG Egan","year":"2014","unstructured":"Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs\u2013FDA and EMA assessment. N Engl J Med. 2014;370(9):794\u20137.","journal-title":"N Engl J Med"},{"key":"499_CR65","unstructured":"Investigation into GLP-1 based diabetes therapies concluded. European Medicines Agency. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2013\/07\/news_detail_001856.jsp&mid=WC0b01ac058004d5c1 . Accessed 12 January 2015."},{"issue":"12","key":"499_CR66","doi-asserted-by":"publisher","first-page":"e214","DOI":"10.2337\/dc13-1542","volume":"36","author":"EA Gale","year":"2013","unstructured":"Gale EA. Response to comment on: Butler et al. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care 2013;36:2118-2125. Diabetes Care. 2013;36(12):e214.","journal-title":"Diabetes Care"},{"issue":"12","key":"499_CR67","doi-asserted-by":"publisher","first-page":"e213","DOI":"10.2337\/dc13-1134","volume":"36","author":"LB Knudsen","year":"2013","unstructured":"Knudsen LB, Nyborg NC, Svendsen CB, Vrang N, Moses AC. Comment on: Butler et al. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care 2013;36:2118-2125. Diabetes Care. 2013;36(12):e213.","journal-title":"Diabetes Care"},{"issue":"4","key":"499_CR68","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1210\/en.2009-1272","volume":"151","author":"L Bjerre Knudsen","year":"2010","unstructured":"Bjerre Knudsen L, Madsen LW, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010;151(4):1473\u201386.","journal-title":"Endocrinology"},{"key":"499_CR69","unstructured":"An active surveillance program for cases of medullary thyroid carcinoma (MTC). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT01511393 . Accessed 28 Dec 2014."},{"issue":"2","key":"499_CR70","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/j.1463-1326.2010.01327.x","volume":"13","author":"WH Polonsky","year":"2011","unstructured":"Polonsky WH, Fisher L, Hessler D, Bruhn D, Best JH. Patient perspectives on once-weekly medications for diabetes. Diabetes Obes Metab. 2011;13(2):144\u20139.","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"499_CR71","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/j.1464-5491.2009.02752.x","volume":"26","author":"JH Best","year":"2009","unstructured":"Best JH, Boye KS, Rubin RR, Cao D, Kim TH, Peyrot M. Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily. Diabet Med. 2009;26(7):722\u20138.","journal-title":"Diabet Med"},{"issue":"2","key":"499_CR72","doi-asserted-by":"publisher","first-page":"314","DOI":"10.2337\/dc10-1119","volume":"34","author":"JH Best","year":"2011","unstructured":"Best JH, Rubin RR, Peyrot M, et al. Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26\u00a0weeks of treatment. Diabetes Care. 2011;34(2):314\u20139.","journal-title":"Diabetes Care"},{"key":"499_CR73","unstructured":"Saunders W, Nguyen H, Kalsekar I. Real-world comparative effectiveness of exenatide once weekly and liraglutide in patients with type 2 diabetes mellitus. 74th Scientific Sessions of the American Diabetes Association. 2014. Poster 1192."},{"issue":"6","key":"499_CR74","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.2337\/dc12-0413","volume":"35","author":"SE Inzucchi","year":"2012","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364\u201379.","journal-title":"Diabetes Care"},{"issue":"Suppl 2","key":"499_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/EP.17.S2.1","volume":"17","author":"Y Handelsman","year":"2011","unstructured":"Handelsman Y, Mechanick JI, Blonde L, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract. 2011;17(Suppl 2):1\u201353.","journal-title":"Endocr Pract"},{"key":"499_CR76","unstructured":"Buse JB, Peters A, Russell-Jones D, et al (2015) Is insulin the most effective injectable antihyperglycaemic therapy? Diabetes Obes Metab. 2015;17(2):145\u201351."},{"issue":"1","key":"499_CR77","doi-asserted-by":"publisher","first-page":"140","DOI":"10.2337\/dc14-2441","volume":"38","author":"SE Inzucchi","year":"2015","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140\u20139.","journal-title":"Diabetes Care"},{"issue":"3","key":"499_CR78","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1185\/03007995.2013.852078","volume":"30","author":"R Goldenberg","year":"2014","unstructured":"Goldenberg R. Insulin plus incretin agent combination therapy in type 2 diabetes: a systematic review. Curr Med Res Opin. 2014;30(3):431\u201345.","journal-title":"Curr Med Res Opin"},{"key":"499_CR79","doi-asserted-by":"crossref","unstructured":"Eng C, Kramer CK, Zinman B, Retnakaran R. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet. 2014;384(9961):2228\u201334.","DOI":"10.1016\/S0140-6736(14)61335-0"},{"key":"499_CR80","unstructured":"Phase III study to evaluate safety and efficacy of added exenatide versus placebo to titrated basalinsulin glargine in inadequately controlled patients with type II diabetes mellitus clinicaltrials.gov. 2015. https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT02229383 ."},{"issue":"9","key":"499_CR81","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1016\/j.clinthera.2012.07.007","volume":"34","author":"N Inagaki","year":"2012","unstructured":"Inagaki N, Atsumi Y, Oura T, Saito H, Imaoka T. Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study. Clin Ther. 2012;34(9):1892\u20131908e1.","journal-title":"Clin Ther"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-017-0499-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-017-0499-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-017-0499-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,28]],"date-time":"2019-09-28T06:42:39Z","timestamp":1569652959000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-017-0499-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,3]]},"references-count":81,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["499"],"URL":"https:\/\/doi.org\/10.1007\/s12325-017-0499-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,3]]},"assertion":[{"value":"22 March 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2017","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}